Fig. 6: Anti-tumor memory immune response induced by FLICs-loaded hydrogel implants in C57BL/6J mice.
From: Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy
a Schematic illustrating the experimental procedure and the time schedule for evaluating anti-tumor memory immune response. Tumor rechallenge was performed via subcutaneous injection of B16F10 melanoma cells (1 × 105) at the resection site on day 14 after tumor removal. b Ratios of central memory-like (CD44+CD62L+) CD8+ T cells were evaluated in the spleens of control (naive) and treated (FLICs-loaded hydrogel implants and FRL illumination) mice sacrificed on day 14. Quantification of CD44+CD62L+CD8+ T cells. c Ratios of central memory-like CD8+ T cells were evaluated in peripheral blood of control (naive) and treated (FLICs-loaded hydrogel implants and FRL illumination) mice on day 14 by flow cytometric analysis. Quantification of central memory-like CD8+ T cells. d In vivo bioluminescence imaging of tumor burden performed on day 25 and day 36 after tumor resection (i.e., 11 and 22 days after rechallenge). Five mice per group are shown. Quantification of tumor burden based on bioluminescence IVIS imaging data from d on day 25 (e) and day 36 (f). g Kaplan-Meier curve of survival following tumor rechallenge (n = 5 mice). Data in b, c, e, f are presented as the mean ± SEM (b, c, n = 4 mice; e, f, n = 5 mice). P values were calculated by two-tailed unpaired t-test. **P < 0.01, ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file.
